Goodwin has strong expertise in ERISA and executive compensation, offering experience to advising clients on the full spectrum of compensation and benefits matters. Co-chaired by Patrick Menasco in Washington DC, and James Mattus in Boston, the team is known for its deep expertise in M&A, IPOs, private equity, and fiduciary issues under ERISA. The firm is a go-to advisor for financial institutions, investment funds, and emerging growth companies, offering strategic counsel on equity arrangements, golden parachutes, and retirement plan structures.
Legal 500 Editorial commentary
Key clients
- Astera Labs, Inc.
- ImmuNext, Inc.
- Human Immunology Biosciences (HI-Bio)
- Fusion Pharmaceuticals
- Century Therapeutics
- Deciphera
- Charlesbank Capital Partners, LLC
- AVROBIO
- Marlin Equity Partners
- Exabeam, Inc.
Work highlights
- Advised Astera Labs on the employee benefits and executive compensation aspects of its $774 million initial public offering.
- Advised Human Immunology Biosciences (HI-Bio™) on the employee benefits and executive compensation aspects of its $1.15 billion acquisition by Biogen.
- Advised TowerBrook Capital Partners L.P. on the employee benefits and executive compensation aspects of its majority equity investment inLiftWerx Holdings Inc.
Lawyers
Practice head
Patrick Menasco, James Mattus
Other key lawyers
Lynda Galligan; Natascha George; Monica Patel